Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Mesoblast Limited

Biotech Giants' SG&A Expenses: A Decade of Change

__timestampMesoblast LimitedUltragenyx Pharmaceutical Inc.
Wednesday, January 1, 20145417000010811000
Thursday, January 1, 20156537800033001000
Friday, January 1, 20165226300064936000
Sunday, January 1, 20173507200099909000
Monday, January 1, 201827415000127724000
Tuesday, January 1, 201936983000161524000
Wednesday, January 1, 202050918000182933000
Friday, January 1, 202163586000219982000
Saturday, January 1, 202257967000278139000
Sunday, January 1, 202353107000309799000
Monday, January 1, 202423626000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Mesoblast Limited from 2014 to 2023. Ultragenyx, a leader in rare disease treatments, has seen its SG&A expenses skyrocket by over 2,700% from 2014 to 2023, reflecting its aggressive growth strategy. In contrast, Mesoblast, known for its regenerative medicine, experienced a more modest 56% increase over the same period. Notably, Ultragenyx's expenses surpassed Mesoblast's by nearly 500% in 2023, highlighting its expansive operational scale. However, Mesoblast's expenses showed a decline in 2024, indicating potential cost optimization or strategic shifts. This financial snapshot underscores the diverse strategies these companies employ in navigating the biotech landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025